

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	10/5/6.837
Source:	P.47/10
Date Processed by STIC:	12/17/04
•	

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS; PLEASE USE THE <u>CHECKER</u> <u>VERSION 4.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
 U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/5/6,837
ATTN: NEW RULES CASES:	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
1Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
·2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters , instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6PatentIn 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

AMC - Biotechnology Systems Branch - 09/09/2003



PCT

RAW SEQUENCE LISTING

DATE: 12/17/2004

PATENT APPLICATION: US/10/516,837

TIME: 15:14:52

Input Set : A:\BTG0008-101(144404US01).SEQ.txt
Output Set: N:\CRF4\12172004\J516837.raw

```
3 <110> APPLICANT: ISIS INNOVATION LIMITED
               ANDERSON, Robert Paul
               HILL, Adrian Vivian Sinton
               JEWELL, Derek Parry
      8 <120> TITLE OF INVENTION: THERAPEUTIC EPITOPES AND USES THEREOF
     10 <130> FILE REFERENCE: 142769 / P035468WO
C--> 12 <140> CURRENT APPLICATION NUMBER: US/10/516,837
C--> 13 <141> CURRENT FILING DATE: 2004-12-03
     15 <150> PRIOR APPLICATION NUMBER: GB 0212885.8
                                                                                  Does Not Comply
     16 <151> PRIOR FILING DATE: 2002-06-05
                                                                             Corrected Diskette Needer
     18 <160> NUMBER OF SEQ ID NOS: 758
     20 <170> SOFTWARE: SeqWin99, version 1.02
     22 <210> SEQ ID NO: 1
     23 <211> LENGTH: 7
     24 <212> TYPE: PRT
     21 <220> FEATURE:
28 <223> OTHER INFORMATION: (peptide) insufficient liplaration-girl source of genetic
30 <400> SEQUENCE: 1
31 Pro Gln Pro Glu Leu Pro Tyr

32 1 5

34 <210> SEQ ID NO: 2

35 <211> LENGTH: 17
36 <212> TYPE: PRT
37 <213> ORGANISM: Artificial Sequence
     37 <213> ORGANISM: Artificial Sequence
     39 <220> FEATURE:
     40 <223 > OTHER INFORMATION: (peptide) same end
     42 <400> SEQUENCE: 2
     43 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Gln
                                                  10
     46 Ser
     49 <210> SEO ID NO: 3
     50 <211> LENGTH: 266
     51 <212> TYPE: PRT
     52 <213> ORGANISM: Homo sapiens
     54 <400> SEQUENCE: 3
     55 Val Arg Val Pro Val Pro Gln Leu Gln Pro Gln Asn Pro Ser Gln Gln
                                                  10
     58 Gln Pro Gln Glu Gln Val Pro Leu Val Gln Gln Gln Phe Pro Gly
                      20
                                             25
     61 Gln Gln Gln Phe Pro Pro Gln Gln Pro Tyr Pro Gln Pro Gln Pro
                                        40
     64 Phe Pro Ser Gln Gln Pro Tyr Leu Gln Leu Gln Pro Phe Pro Gln Pro
```





RAW SEQUENCE LISTING DATE: 12/17/2004 PATENT APPLICATION: US/10/516,837 TIME: 15:14:52

Input Set : A:\BTG0008-101(144404US01).SEQ.txt Output Set: N:\CRF4\12172004\J516837.raw

67 Gln Leu Pro Tyr Pro Gln Pro Gln Ser Phe Pro Pro Gln Gln Pro Tyr
68 65 70 75 80
70 Pro Gln Pro Gln Pro Gln Tyr Ser Gln Pro Gln Gln Pro Ile Ser Gln
71 85 90 95
73 Gln Gln Ala Gln
74 100 105 110
76 Gln Ile Leu Gln Gln Ile Leu Gln Gln Leu Ile Pro Cys Met Asp
77 115 120 125
79 Val Val Leu Gln Gln His Asn Ile Ala His Ala Arg Ser Gln Val Leu
80 130 135 140
82 Gln Gln Ser Thr Tyr Gln Leu Leu Gln Glu Leu Cys Cys Gln His Leu
83 145 150 155 160
85 Trp Gln Ile Pro Glu Gln Ser Gln Cys Gln Ala Ile His Asn Val Val
86 165 170 175
88 His Ala Ile Ile Leu His Gln Gln Gln Lys Gln Gln Gln Pro Ser 89 180 185 190
89 180 185 190 91 Ser Gln Val Ser Phe Gln Gln Pro Leu Gln Gln Tyr Pro Leu Gly Gln
92 195 200 205
94 Gly Ser Phe Arg Pro Ser Gln Gln Asn Pro Gln Ala Gln Gly Ser Val
95 210 215 220
97 Gln Pro Gln Gln Leu Pro Gln Phe Glu Glu Ile Arg Asn Leu Ala Leu
98 225 230 235 240
100 Gln Thr Leu Pro Ala Met Cys Asn Val Tyr Ile Ala Pro Tyr Cys Thr
101 245 250 255
103 Ile Ala Pro Phe Gly Ile Phe Gly Thr Asn
104 260 265
106 <210> SEQ ID NO: 4
107 <211> LENGTH: 7
108 <212> TYPE: PRT
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE:
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE:
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: peptide
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: peptide 126 <400> SEQUENCE: 5
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: peptide
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION; peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION; peptide 126 <400> SEQUENCE: 5 127 Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro 128 1 5 10 15
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION: peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: peptide 126 <400> SEQUENCE: 5 127 Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION peptide 126 <400> SEQUENCE: 5 127 Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro 128 1 5 10 15 130 Gln Ser Phe Pro
108 <212> TYPE: PRT 109 <213> ORGANISM: Artificial Sequence 111 <220> FEATURE: 112 <223> OTHER INFORMATION peptide 114 <400> SEQUENCE: 4 115 Pro Gln Pro Gln Leu Pro Tyr 116 1 5 118 <210> SEQ ID NO: 5 119 <211> LENGTH: 20 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION peptide 126 <400> SEQUENCE: 5 127 Leu Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro 128 1 5 10 15 130 Gln Ser Phe Pro 131 20



RAW SEQUENCE LISTING DATE: 12/17/2004
PATENT APPLICATION: US/10/516,837 TIME: 15:14:52

Input Set : A:\BTG0008-101(144404US01).SEQ.txt
Output Set: N:\CRF4\12172004\J516837.raw

```
135 <212> TYPE: PRT
136 <213> ORGANISM: Artificial Sequence
138 <220> FEATURE:
139 <223> OTHER INFORMATION: / peptide
141 <400> SEQUENCE: 6
142 Glu Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Gln
143 1
145 Ser
148 <210> SEQ ID NO: 7
149 <211> LENGTH: 17
150 <212> TYPE: PRT
151 <213> ORGANISM: Artificial Sequence
153 <220> FEATURE:
154 <223> OTHER INFORMATION: peptide
156 <400> SEQUENCE: 7
157 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Glu
158 1
160 Ser
163 <210> SEQ ID NO: 8
164 <211> LENGTH: 17
165 <212> TYPE: PRT
166 <213> ORGANISM: Artificial Sequence
168 <220> FEATURE:
169 <223> OTHER INFORMATION / peptide
171 <400> SEQUENCE: 8
172 Glu Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro Glu
173 1
                    5
175 Ser
178 <210> SEQ ID NO: 9
179 <211> LENGTH: 5
180 <212> TYPE: PRT
181 <213> ORGANISM: Artificial Sequence
183 <220> FEATURE:
184 <223> OTHER INFORMATION:/
                             'peptide
186 <400> SEQUENCE: 9
187 Gln Pro Gln Leu Pro
188 1
190 <210> SEQ ID NO: 10
191 <211> LENGTH: 17
192 <212> TYPE: PRT
193 <213> ORGANISM: Artificial Sequence
195 <220> FEATURE:
196 <223> OTHER INFORMATION peptide
198 <400> SEQUENCE: 10
199 Gln Leu Gln Pro Phe Pro Gln Pro Gln Leu Pro Tyr Pro Gln Pro Gln
200 1
                    5
202 Ser
205 <210> SEQ ID NO: 11
```

206 <211> LENGTH: 20





RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/516,837

TIME: 15:14:52

DATE: 12/17/2004

Input Set : A:\BTG0008-101(144404US01).SEQ.txt

Output Set: N:\CRF4\12172004\J516837.raw

```
207 <212> TYPE: PRT
208 <213> ORGANISM: Artificial Sequence
210 <220> FEATURE:
211 <223> OTHER INFORMATION, peptide
213 <400> SEQUENCE: 11
214 Leu Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln Pro
215 1
                                         10
217 Gln Ser Phe Pro
218
220 <210> SEQ ID NO: 12
221 <211> LENGTH: 5
222 <212> TYPE: PRT
223 <213> ORGANISM: Artificial Sequence
225 <220> FEATURE:
226 <223> OTHER INFORMATION: peptide
228 <400> SEQUENCE: 12
229 Pro Gln Leu Pro Tyr
230 1
232 <210> SEQ ID NO: 13
233 <211> LENGTH: 12
234 <212> TYPE: PRT
235 <213> ORGANISM: Artificial Sequence
237 <220> FEATURE:
238 <223> OTHER INFORMATION:/peptide
240 <400> SEQUENCE: 13
241 Gln Leu Gln Pro Phe Pro Gln Pro Glu Leu Pro Tyr
242 1
                    5
244 <210> SEQ ID NO: 14
245 <211> LENGTH: 11
246 <212> TYPE: PRT
247 <213> ORGANISM: Artificial Sequence
249 <220> FEATURE:
250 <223> OTHER INFORMATION: peptide
252 <400> SEQUENCE: 14
253 Pro Phe Pro Gln Pro Glu Leu Pro Tyr Pro Gln
254 1
256 <210> SEQ ID NO: 15
257 <211> LENGTH: 14
258 <212> TYPE: PRT
259 <213> ORGANISM: Artificial Sequence
261 <220> FEATURE:
262 <223> OTHER INFORMATION: (peptide
264 <400> SEQUENCE: 15
265 Pro Arg Ala Pro Trp Ile Glu Glu Glu Gly Pro Glu Tyr Trp
266 1
268 <210> SEQ ID NO: 16
269 <211> LENGTH: 16
```

271 <213> ORGANISM: Artificial Sequence

270 <212> TYPE: PRT





RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/516,837

DATE: 12/17/2004 TIME: 15:14:52

Input Set : A:\BTG0008-101(144404US01).SEQ.txt

Output Set: N:\CRF4\12172004\J516837.raw

```
273 <220> FEATURE:
274 <223> OTHER INFORMATION: peptide
276 <400> SEQUENCE: 16
277 Ile Asp Val Trp Leu Gly Gly Leu Leu Ala Glu Asn Phe Leu Pro Tyr
278 1
                                         10
281 <210> SEQ ID NO: 17
282 <211> LENGTH: 17
283 <212> TYPE: PRT
284 <213> ORGANISM: Artificial Sequence
286 <220> FEATURE:
287 <223> OTHER INFORMATION: peptide
289 <400> SEQUENCE: 17
290 Pro Gln Pro Gln Pro Phe Pro Pro Glu Leu Pro Tyr Pro Gln Pro Gln
291 1
293 Ser
296 <210> SEQ ID NO: 18
297 <211> LENGTH: 9
298 <212> TYPE: PRT
299 <213> ORGANISM: Artificial Sequence
301 <220> FEATURE:
302 <223> OTHER INFORMATION: (peptide
304 <400> SEQUENCE: 18
305 Phe Pro Gln Pro Gln Leu Pro Tyr Pro
306 1
308 <210> SEQ ID NO: 19
309 <211> LENGTH: 9
310 <212> TYPE: PRT
311 <213> ORGANISM: Artificial Sequence
313 <220> FEATURE:
314 <223> OTHER INFORMATION peptide
316 <400> SEQUENCE: 19
317 Phe Pro Gln Pro Gln Gln Pro Phe Pro
318 1
320 <210> SEQ ID NO: 20
321 <211> LENGTH: 9
322 <212> TYPE: PRT
323 <213> ORGANISM: Artificial Sequence
325 <220> FEATURE:
326 <223> OTHER INFORMATION: peptide
328 <400> SEQUENCE: 20
329 Pro Gln Gln Pro Gln Gln Pro Phe Pro
330 1
332 <210> SEQ ID NO: 21
333 <211> LENGTH: 12
334 <212> TYPE: PRT
335 <213> ORGANISM: Artificial Sequence
337 <220> FEATURE:
338 <223> OTHER INFORMATION: peptide
340 <400> SEQUENCE: 21
```

The types of errors shown exist throughout the Sequence Listing. Please check subsequent sequences for similar errors.



RAW SEQUENCE LISTING ERROR SUMMARY PATENT APPLICATION: US/10/516,837

DATE: 12/17/2004 TIME: 15:14:53

Input Set : A:\BTG0008-101(144404US01).SEQ.txt

Output Set: N:\CRF4\12172004\J516837.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seg#:23; Xaa Pos. 1,2,3,4,5,6,7,10,11,12,13,14,15,16,17

Seq#:37; Xaa Pos. 2

Seq#:38; Xaa Pos. 2,3,4

Seq#:45; Xaa Pos. 3,5
Seq#:64; Xaa Pos. 2





VERIFICATION SUMMARY

PATENT APPLICATION: US/10/516,837

DATE: 12/17/2004 TIME: 15:14:53

Input Set : A:\BTG0008-101(144404US01).SEQ.txt

Output Set: N:\CRF4\12172004\J516837.raw

L:12 M:270 C: Current Application Number differs, Replaced Current Application Number

L:13 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:379 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:23

L:379 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23 after pos.:0

M:341 Repeated in SeqNo=23

L:593 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:37

L:593 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37 after pos.:0

L:613 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:38

L:613 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38 after pos.:0

L:708 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:45

L:708 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:45 after pos.:0

L:955 M:258 W: Mandatory Feature missing, <221> Tag not found for SEQ ID#:64

L:955 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:64 after pos.:0